Seizures as an Adverse Event of Cellular Therapy in Pediatric Neurological Disorders and its Prevention

Sharma, Alok; Sane, Hemangi; Paranjape, Amruta; Gokulchandran, Nandini; Takle, Mansi; Badhe, Prerna

doi:10.4172/2329-6895.1000164

Cited by 2 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, 116 patients had a history of seizures before intervention while 62 patients had an abnormal electroencephalogram (EEG). Patients who already had abnormal EEG or had a history of seizures were advised prophylactic antiepileptic protocol which reduces the chances of occurrence of seizures post cell therapy [52]. In this study, only 9 out of 1011 (0.9%) patients had seizures as an AE post cell therapy.…”

Section: Cell Therapy Related Aesmentioning

confidence: 78%

Autologous Bone Marrow Mononuclear Cell Administration in a Large Cohort Of 1011 Autism Spectrum Disorder Patients: A Clinical Study

Sharma¹,

Gokulchandran²,

Sane³

et al. 2023

Preprint

View full text Add to dashboard Cite

Bone marrow mononuclear cells (BMMNCs) have emerged as a potential therapeutic strategy for various incurable conditions including autism spectrum disorder (ASD). To study its safety and efficacy, we analyzed 1011 patients who underwent intrathecal administration of autologous BMMNCs along with neurorehabilitation. At mean follow-up of 19.3 months after intervention, 90.6% patients showed overall improvement. Improvements were observed in attention concentration, command following, eye contact, sitting tolerance, social interaction, hyperactivity, communication, speech, aggressiveness, stereotypical and self-injurious behavior. Statistically significant changes were observed in scores of Indian Scale of Autism Assessment and Childhood Autism Rating Scale (p<0.05). On subgroup analysis, improvements were recorded irrespective of age and disease severity and better outcome was observed in patients who took multiple doses of cell therapy compared to single dose. Comparative Brain PET-CT scan of 401 patients showed improved brain metabolism after the intervention. No major adverse events were reported. Only 9 out of 1011 patients experienced seizures which were managed using medications. 4 out of 9 had history of seizures while 5 had normal EEG with no history. However, improvements were still observed in these 9 patients. Thus, intrathecal transplantation of autologous BMMNCs along with neurorehabilitation is safe and efficacious in patients with ASD.

show abstract

Section: Cell Therapy Related Aesmentioning

confidence: 78%

Autologous Bone Marrow Mononuclear Cell Administration in a Large Cohort Of 1011 Autism Spectrum Disorder Patients: A Clinical Study

Sharma¹,

Gokulchandran²,

Sane³

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Pre-existing epileptogenic focus in Electroencephalogram (EEG) also predicts the occurrence of seizures. Evidence suggests that antiepileptic prophylactic regimen decreases the incidence of seizures as an adverse event after stem cell therapy [93].…”

Section: Adverse Events Of Stem Cell Therapymentioning

confidence: 99%

Stem Cell Therapy in Pediatric Neurological Disabilities

Sharma¹,

Sane²,

Gokulchandran³

et al. 2017

Physical Disabilities - Therapeutic Implications

Self Cite

View full text Add to dashboard Cite

Pediatric neurological disorders represent a major part of the disabilities worldwide. In over 10 decades of research to find a cure for these disorders, medical science has not been able to repair the underlying brain injury. This chapter focuses on recent advances in the application of stem cells as a therapeutic tool for some of the common neurodevelopmental disorders (cerebral palsy, autism, intellectual disability and muscular dystrophy). The mechanism of action of stem cells in each disorder has been explained. A review of clinical data has been described giving a clear understanding of current status of stem cell therapy in these disorders. Various factors influencing the outcome of stem cell therapy such as different types of cells, different routes of administration and dosage and frequency of transplantation have also been discussed. Our experience of treating these disorders is exhibited in the form of our published data. Use of novel monitoring tools such as MRI MSK and PET-CT scan brain to track the changes occurring at cellular level after stem cell therapy are described. We also highlight the importance of a multidisciplinary approach of combining rehabilitation with stem cell therapy.

show abstract

Seizures as an Adverse Event of Cellular Therapy in Pediatric Neurological Disorders and its Prevention

Cited by 2 publications

References 32 publications

Autologous Bone Marrow Mononuclear Cell Administration in a Large Cohort Of 1011 Autism Spectrum Disorder Patients: A Clinical Study

Autologous Bone Marrow Mononuclear Cell Administration in a Large Cohort Of 1011 Autism Spectrum Disorder Patients: A Clinical Study

Stem Cell Therapy in Pediatric Neurological Disabilities

Contact Info

Product

Resources

About